Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5736978 | 0.89 | KMT2A (0.50) | KMT2AALDH1A1KDM4EHSD17B10TSHR | |
| SCHEMBL18698097 | 0.86 | KMT2A (0.44) | KMT2AALDH1A1KDM4EHSD17B10TSHR | |
| SCHEMBL5737042 | 0.83 | KMT2A (0.48) | KMT2AALDH1A1KDM4ETSHRPOLB | |
| SCHEMBL13724813 | 0.82 | KMT2A (0.45) | KMT2AALDH1A1KDM4EHSD17B10POLB | |
| SCHEMBL3714556 | 0.79 | MAPT (0.40) | KMT2AALDH1A1KDM4EHSD17B10TSHR | |
| SCHEMBL20002727 | 0.78 | MMP8 (0.41) | KMT2AALDH1A1KDM4ETSHRMMP8 | |
| SCHEMBL3718145 | 0.78 | L3MBTL1 (0.49) | KMT2AALDH1A1KDM4EGAAMEN1 | |
| SCHEMBL1065575 | 0.77 | KMT2A (0.48) | KMT2AALDH1A1KDM4EHSD17B10TSHR | |
| SCHEMBL27713100 | 0.77 | CYP4F2 (0.47) | KMT2AALDH1A1KDM4EHSD17B10TSHR | |
| SCHEMBL1246314 | 0.76 | KMT2A (0.63) | KMT2AALDH1A1KDM4ETSHRGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11518766-B2 | Tricyclic compound, preparation method therefor and use thereof | SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD. (CN) | 2022-12-06 | — | — | US | disclosed |
| EP-2701512-B1 | ALDOSTERONE SYNTHASE INHIBITORS | MERCK SHARP & DOHME (US) | 2017-04-05 | — | — | EP | disclosed |
| EP-2701512-B1 | ALDOSTERONE SYNTHASE INHIBITORS | MERCK SHARP & DOHME (US) | 2017-04-05 | — | — | EP | disclosed |
| US-9073929-B2 | Aldosterone synthase inhibitors | ELEXOPHARM GMBH (DE) | 2015-07-07 | — | — | US | disclosed |
| US-9073929-B2 | Aldosterone synthase inhibitors | ELEXOPHARM GMBH (DE) | 2015-07-07 | — | — | US | disclosed |
| US-9073929-B2 | Aldosterone synthase inhibitors | ELEXOPHARM GMBH (DE) | 2015-07-07 | — | — | US | disclosed |
| EP-2701512-A1 | ALDOSTERONE SYNTHASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2014-03-05 | — | — | EP | disclosed |
| US-20140045819-A1 | ALDOSTERONE SYNTHASE INHIBITORS | ELEXOPHARM GMBH (DE) | 2014-02-13 | — | — | US | disclosed |
| US-20140045819-A1 | ALDOSTERONE SYNTHASE INHIBITORS | ELEXOPHARM GMBH (DE) | 2014-02-13 | — | — | US | disclosed |
| US-20140045819-A1 | ALDOSTERONE SYNTHASE INHIBITORS | ELEXOPHARM GMBH (DE) | 2014-02-13 | — | — | US | disclosed |
| WO-2012148808-A1 | ALDOSTERONE SYNTHASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-11-01 | — | — | WO | disclosed |
| WO-2010116270-A1 | EP2/4 AGONISTS | PFIZER INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010116270-A1 | EP2/4 AGONISTS | PFIZER INC. (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11518766-B2 | Tricyclic compound, preparation method therefor and use thereof | TFPI, TFPI2, F11 | KMT2A 2513/4885ALDH1A1 3573/4885KDM4E 3192/4885 |
| US-20140045819-A1 | ALDOSTERONE SYNTHASE INHIBITORS | CYP21A2, CYP17A1, HSD11B1 | KMT2A 3527/4885ALDH1A1 290/4885KDM4E 2899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.